Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Rating) dropped 5.5% during mid-day trading on Wednesday . The company traded as low as $12.75 and last traded at $12.88. Approximately 98,424 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 322,177 shares. The stock had previously closed at $13.63.
Analyst Ratings Changes
Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Dyne Therapeutics from $24.00 to $18.00 in a research report on Tuesday, November 29th. Raymond James raised their price target on shares of Dyne Therapeutics from $15.00 to $16.00 and gave the company an “outperform” rating in a research note on Friday, November 4th. Finally, StockNews.com initiated coverage on Dyne Therapeutics in a research report on Wednesday, October 12th. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.60.
Dyne Therapeutics Stock Performance
The business has a 50 day simple moving average of $11.89 and a 200-day simple moving average of $11.95. The stock has a market capitalization of $675.04 million, a P/E ratio of -3.89 and a beta of 0.07.
Insider Activity at Dyne Therapeutics
In related news, insider Jonathan Mcneill sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion of the sale, the insider now owns 67,600 shares in the company, valued at approximately $948,428. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Dyne Therapeutics news, insider Jonathan Mcneill sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $14.03, for a total transaction of $140,300.00. Following the completion of the sale, the insider now directly owns 67,600 shares in the company, valued at approximately $948,428. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jason P. Rhodes bought 934,581 shares of the stock in a transaction on Monday, December 12th. The shares were acquired at an average cost of $10.70 per share, for a total transaction of $10,000,016.70. Following the purchase, the director now owns 934,581 shares in the company, valued at $10,000,016.70. The disclosure for this purchase can be found here. Insiders sold 41,213 shares of company stock worth $500,690 in the last quarter. 42.34% of the stock is owned by company insiders.
Institutional Trading of Dyne Therapeutics
Institutional investors have recently bought and sold shares of the company. Swiss National Bank raised its position in Dyne Therapeutics by 7.6% during the first quarter. Swiss National Bank now owns 54,900 shares of the company’s stock valued at $529,000 after acquiring an additional 3,900 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Dyne Therapeutics by 57.0% during the first quarter. MetLife Investment Management LLC now owns 19,766 shares of the company’s stock valued at $191,000 after buying an additional 7,180 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Dyne Therapeutics by 39.6% in the first quarter. Dimensional Fund Advisors LP now owns 50,278 shares of the company’s stock worth $484,000 after buying an additional 14,266 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Dyne Therapeutics by 2.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 192,477 shares of the company’s stock worth $1,856,000 after acquiring an additional 3,918 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of Dyne Therapeutics by 2,368.9% in the 1st quarter. UBS Group AG now owns 10,172 shares of the company’s stock valued at $98,000 after acquiring an additional 9,760 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Get a free copy of the StockNews.com research report on Dyne Therapeutics (DYN)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.